GlassScriptPhysician profile
George F Geils
NPI 1093773657
$75,715.41
in general payments reported to CMS, 2019-2025
77 companies · $2,405 in 2025
The $2,405 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $39K · 2020: $4,520 · 2021: $1,928 · 2022: $2,957 · 2023: $9,699 · 2024: $15K · 2025: $2,405.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $16K · Food and Beverage: $7,711 · Travel and Lodging: $2,798 · Education: $26.33.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $16,353.00 |
| Food and Beverage | $7,710.71 |
| Travel and Lodging | $2,797.70 |
| Education | $26.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $20,275.12 | 2019-2025 | |
| Amgen INC. | $15,331.38 | 2019-2023 | Kyprolis, Blincyto, Lumakras |
| E.R. Squibb & Sons, L.L.C. | $14,073.53 | 2019-2025 | Opdivo |
| Janssen Biotech, INC. | $9,849.06 | 2019-2025 | Darzalex, Tecvayli, Erleada |
| Celgene Corporation | $3,834.06 | 2019-2025 | Reblozyl, Pomalyst |
| Merck Sharp & Dohme LLC | $1,445.82 | 2019-2025 | Keytruda, Welireg, Lynparza |
| Novartis Pharmaceuticals Corporation | $878.40 | 2019-2024 | |
| Astrazeneca Pharmaceuticals LP | $823.49 | 2019-2025 | Enhertu, Calquence, Tagrisso |
| Pfizer INC. | $664.96 | 2019-2025 | |
| Mckesson Specialty Care Distribution, LLC | $588.86 | 2019-2020 | |
| Daiichi Sankyo INC. | $540.82 | 2019-2025 | Injectafer, Enhertu, Datroway |
| Lilly USA, LLC | $521.11 | 2019-2025 | Jaypirca, Verzenio, Retevmo |
| Astellas Pharma US INC | $518.61 | 2019-2025 | Cresemba, Xospata |
| Genentech USA, INC. | $409.97 | 2019-2025 | Polivy, Venclexta, Lunsumio |
| Seagen INC. | $382.00 | 2019-2023 | Adcetris |
Show all 75 companies
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw George Geils listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.